FCGRT and non-small cell lung carcinoma: In that context, it will be interesting to evaluate the predictive value of FcRn in response to immunomodulatory monoclonal antibodies, targeting immune checkpoints (anti-PD-1 or anti-CTLA-4) that have raised great promises in the treatment of NSCLC [30, 31].